Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Current renal cell carcinoma (RCC) treatments have limited efficacy and drug resistance is a significant challenge.
• Oridonin, a natural diterpenoid, exhibits antitumor properties, necessitating the development of more potent analogs.
• Previous work established synthetic routes for diverse oridonin analogs, including nitrogen-enriched variants.

Purpose of the Study:

• To screen and identify novel oridonin analogs with enhanced cytotoxicity against drug-resistant RCC.
• To evaluate the therapeutic potential of the lead compound, CYD-6-17, in preclinical models of RCC.
• To elucidate the molecular mechanism of action of CYD-6-17 in targeting resistant RCC.

Main Methods:

• Cytotoxicity screening of oridonin analogs using MTT assays.
• In vitro evaluation of CYD-6-17 against drug-resistant RCC and endothelial cells.
• In vivo efficacy studies using a xenograft model of RCC.
• Mechanistic studies investigating the target gene, 3-phosphoinositide-dependent protein kinase 1 (PDK1).

Main Results:

• CYD-6-17 demonstrated high potency in inhibiting the in vitro growth of drug-resistant RCC cells and tumor-stimulated endothelial cells at nanomolar concentrations.
• Administration of CYD-6-17 significantly suppressed RCC tumor growth in a xenograft mouse model.
• CYD-6-17 was found to target the 3-phosphoinositide-dependent protein kinase 1 (PDK1) gene, a key regulator of AKT signaling.

Conclusions:

• CYD-6-17 is a potent oridonin analog effective against drug-resistant RCC.
• The novel mechanism of action involving PDK1 inhibition presents a new therapeutic avenue for treating resistant RCC.
• CYD-6-17 warrants further investigation as a potential therapeutic agent for patients with drug-resistant renal cell carcinoma.